Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

Inclusion Criteria: * primary refractory or relapsed AML * confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification (Vardiman 2002) * aged at least 18 years Exclusion Criteria: * initial diagnosis of acute promyelocytic leukemia as defined by French-American-British criteria (Bennett 1976) * patient in blast crisis stage of chronic myeloid leukemia * received high-dose cytarabine (total cumulative dose of \>6g/m sq)in last 6 months * interval of \<6 months between first onset of last complete remission and current relapse * those with primary refractory leukemia who have received more than three previous induction cycles * relapsed patients who have received more than three previous treatment regimens